Kuboki Y, Terazawa T, Masuishi T, Nakamura M, et al. Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial. Br J Cancer 2023 Mar 4. doi: 10.1038/s41416-023-02212.
PMID: 36871043